GlassScriptPhysician profile
Kristen E Bisig
NPI 1538731633
$3,039.67
in general payments reported to CMS, 2019-2025
17 companies · $917 in 2025
The $917 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $356 · 2022: $300 · 2023: $854 · 2024: $614 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,383.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $512.05 | 2023-2025 | Vuity, Lumigan, Alphagan P |
| Tarsus Pharmaceuticals, INC. | $445.33 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $440.42 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Alcon Vision LLC | $437.47 | 2022-2025 | Tryptyr, Clareon, Rocklatan |
| Horizon Therapeutics Plc | $346.90 | 2021-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $162.53 | 2021 | |
| Eyevance Pharmaceuticals LLC | $139.27 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $126.71 | 2023 | Acuvue |
| Oyster Point Pharma, INC. | $125.14 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $73.86 | 2021 | |
| Novartis Pharmaceuticals Corporation | $65.70 | 2023 | |
| Thea Pharma INC. | $41.75 | 2024-2025 | Iyuzeh |
| Dompe US, INC. | $39.89 | 2022-2025 | Oxervate |
| Glaukos Corporation | $27.37 | 2025 | Istent Infinite |
| Johnson & Johnson Surgical Vision, INC. | $21.90 | 2023 | Tecnis Simplicity, Tecnis Iol |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $18.47 | 2023 | Cequa |
| Visioneering Technologies, INC. | $14.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Bisig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.